Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | FBP1 | P09467 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8015619 | 0.86 | KDM4E (0.41) | KDM4EALDH1A1HPGDHTTRECQL | |
| SCHEMBL7822677 | 0.79 | KDM4E (0.40) | KDM4EALDH1A1HPGDHTTRECQL | |
| SCHEMBL2423817 | 0.78 | KDM4E (0.47) | KDM4EALDH1A1HPGDHTTRECQL | |
| SCHEMBL3809367 | 0.77 | CYP1A2 (0.53) | KDM4EALDH1A1HPGDHTTRECQL | |
| SCHEMBL162807 | 0.77 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDHTTRECQL | |
| SCHEMBL19358702 | 0.76 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDHTTRECQL | |
| SCHEMBL38659549 | 0.76 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDHTTRECQL | |
| SCHEMBL8552985 | 0.76 | ALDH1A1 (0.53) | KDM4EALDH1A1HPGDHTTRECQL | |
| SCHEMBL20595215 | 0.76 | KDM4E (0.45) | KDM4EALDH1A1HPGDHTTRECQL | |
| SCHEMBL28509975 | 0.76 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDHTTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404246-B1 | 2-aminomethylimidazole mimics of NS4A and their effect thereof on hepatitis C virus NS3 protease | KING ABDULAZIZ UNIVERSITY (SA) | 2025-09-02 | — | — | US | disclosed |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | KING ABDULAZIZ UNIVERSITY (SA) | 2021-03-30 | — | — | US | disclosed |
| US-20200368204-A1 | COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-26 | — | — | US | disclosed |
| US-10821096-B1 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-03 | — | — | US | disclosed |
| US-20200323822-A1 | IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | KING ABDULAZIZ UNIVERSITY (SA) | 2020-10-15 | — | — | US | disclosed |
| EP-0820455-B1 | 5H, 10H-IMIDAZO [1,2-a]INDENO [1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES | AVENTIS PHARMA SA (FR) | 2001-10-31 | — | — | EP | disclosed |
| EP-0820455-A1 | 5H, 10H-IMIDAZO [1,2-a]INDENO [1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES | Aventis Pharma S.A. (FR) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031511-A1 | 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368204-A1 | COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN | MAVS, CUL1, CUL3 | KDM4E 2114/4885ALDH1A1 3525/4885HPGD 2800/4885 |
| US-12404246-B1 | 2-aminomethylimidazole mimics of NS4A and their effect thereof on hepatitis C virus NS3 protease | DPP4, GTF3C4, CTRL | KDM4E 465/4885ALDH1A1 1725/4885HPGD 2707/4885 |
| US-20200323822-A1 | IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, ZC3HAV1 | KDM4E 1213/4885ALDH1A1 1548/4885HPGD 2431/4885 |
| US-10821096-B1 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | MAVS, CUL1, CUL3 | KDM4E 2114/4885ALDH1A1 3525/4885HPGD 2800/4885 |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | HAVCR2, MAVS, ZC3HAV1 | KDM4E 1213/4885ALDH1A1 1548/4885HPGD 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.